Lawrence E. Flaherty

Author

Also Known As

L E Flaherty, L Flaherty, L. E. Flaherty, L. Flaherty, L.E. Flaherty, LAWRENCE FLAHERTY, Lawrence E Flaherty, Lawrence E. Flaherty, Lawrence Flaherty, Lawrence Flaherty#.

143

Publications

8.2K

Citations

H-Index

Concepts

All Affiliations

Wayne State University The Barbara Ann Karmanos Cancer Institute University of Michigan SWOG Cancer Research Network Cancer Research And Biostatistics

About

Lawrence E. Flaherty is an author at Wayne State University specializing in medicine, oncology, and cancer therapeutics.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	21	34	2.3K
2	Health Sciences	7	7	790
3	Education	1	1	32
4	Nursing	1	1	32
5	Allergy	1	1	14

Lawrence E. Flaherty

Publications

7.8K

Citations

H-Index

Page 1

	Year	Citations
High- and Low-Dose Interferon Alfa-2b in High-Risk Melanoma: First Analysis of Intergroup Trial E1690/S9111/C9190 John M. Kirkwood, Joseph G. Ibrahim, Vernon K. Sondak, Journal of Clinical Oncology	2000	915
Randomized Phase III Trial of High-Dose Interleukin-2 Versus Subcutaneous Interleukin-2 and Interferon in Patients With Metastatic Renal Cell Carcinoma David F. McDermott, Meredith M. Regan, Joseph I. Clark, Journal of Clinical Oncology	2004	814
Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial Miguel Martín, Frankie A. Holmes, Bent Ejlertsen, The Lancet Oncology 5-Year AnalysisBreast OncologyOncologyHealth SciencesClinical Trials	2017	578
Phase III Trial Comparing Concurrent Biochemotherapy With Cisplatin, Vinblastine, Dacarbazine, Interleukin-2, and Interferon Alfa-2b With Cisplatin, Vinblastine, and Dacarbazine Alone in Patients With Metastatic Malignant Melanoma (E3695): A Trial Coordinated by the Eastern Cooperative Oncology Group Michael B. Atkins, Jessie J. Hsu, Gary I. Cohen, Journal of Clinical Oncology	2008	322
Combination of vemurafenib and cobimetinib in patients with advanced BRAFV600-mutated melanoma: a phase 1b study Antoni Ribas, René González, Anna C. Pavlick, The Lancet Oncology Phase 1BMedicineMelanomaAdvanced Brafv600-mutated MelanomaPathology	2014	293
Adjuvant Immunotherapy of Resected, Intermediate-Thickness, Node-Negative Melanoma With an Allogeneic Tumor Vaccine: Overall Results of a Randomized Trial of the Southwest Oncology Group Vernon K. Sondak, P. Y. Liu, Ralph J. Tuthill, Journal of Clinical Oncology	2002	222
Phase II evaluation of oral estramustine and oral etoposide in hormone-refractory adenocarcinoma of the prostate. Kenneth J. Pienta, Bruce G. Redman, Mohamad A. Hussain, Journal of Clinical Oncology	1994	221
Phase III Trial of Carboplatin and Paclitaxel With or Without Sorafenib in Metastatic Melanoma Keith T. Flaherty, Sandra J. Lee, Fengmin Zhao, Journal of Clinical Oncology	2012	219
Adjuvant Immunotherapy of Resected, Intermediate-Thickness, Node-Negative Melanoma With an Allogeneic Tumor Vaccine: Impact of HLA Class I Antigen Expression on Outcome Jeffrey A. Sosman, Joseph M. Unger, P. Y. Liu, Journal of Clinical Oncology	2002	206
Surgical Adjuvant Active Specific Immunotherapy for Patients with Stage III Melanoma: The Final Analysis of Data from a Phase III, Randomized, Double-Blind, Multicenter Vaccinia Melanoma Oncolysate Trial Marc K. Wallack, Muthukumaran Sivanandham, Charles M. Balch, Journal of the American College of Surgeons	1998	179

Page 1